Gut Microbiota–Metabolite Signaling in Irritable Bowel Syndrome: From Mechanisms and Candidate Metabotypes to Precision Therapeutics
Microorganisms · 06.11.2026 · 14 (11) · 2562
DOI: 10.3390/microorganisms14112562 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microorganisms, online erschienen am 06.11.2026. Verfasst von Yajing Li und 1 weiteren Autor:innen. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Gansu Provincial Administration of Traditional Chinese Medicine High-Level Key Research Project, Gansu Provincial Higher Education Institutions Industry Support Plan.
Abstract (Originalsprache)
Irritable bowel syndrome (IBS) is a heterogeneous disorder of gut–brain interaction in which the same bowel-habit subtype can arise from different biological processes. This narrative review maps microbiota-related bile acids, short-chain fatty acids (SCFAs), tryptophan metabolites, lipopolysaccharide (LPS), neuroactive amines, and fatty acid ethanolamides to host sensors and barrier, immune, motor, and sensory outcomes. Its contribution is a pathway-specific assessment of the evidence needed for clinical use: analytical and temporal reproducibility, demonstration of the proposed mechanism in humans, and prediction of differential treatment benefit. We distinguish descriptive associations, preclinical mechanisms, human pharmacodynamic effects, and validated treatment-selection biomarkers. Bile acid dysregulation offers the most developed connection between a measurable physiological abnormality and a tractable pathway, although biomarker changes do not establish symptom benefit or validate every proposed selection threshold. Most other candidate metabotypes lack externally validated classification rules and prospective treatment-by-biomarker interaction evidence. Diet, transit, medications, sex and hormonal context, and subtype transitions can modify both microbial function and measured metabolite exposure. Accordingly, proposed metabotypes remain research constructs. We integrate microbial transformations and endocrine cross-talk with an evidence ledger that identifies the missing human and predictive links, providing a testable agenda for mechanism-based treatment rather than a clinically validated prescribing algorithm.
Förderung
- National Natural Science Foundation of China
- Gansu Provincial Administration of Traditional Chinese Medicine High-Level Key Research Project
- Gansu Provincial Higher Education Institutions Industry Support Plan
Zitieren
APA
Li, Y., & Liu, J. (2026). Gut Microbiota–Metabolite Signaling in Irritable Bowel Syndrome: From Mechanisms and Candidate Metabotypes to Precision Therapeutics. Microorganisms, 14(11), 2562. https://doi.org/10.3390/microorganisms14112562
Vancouver
Li Y, Liu J. Gut Microbiota–Metabolite Signaling in Irritable Bowel Syndrome: From Mechanisms and Candidate Metabotypes to Precision Therapeutics. Microorganisms. 2026;14(11):2562. doi:10.3390/microorganisms14112562
BibTeX
@article{Li2026,
author = {Li, Yajing and Liu, Junhong},
title = {Gut Microbiota–Metabolite Signaling in Irritable Bowel Syndrome: From Mechanisms and Candidate Metabotypes to Precision Therapeutics},
journal = {Microorganisms},
year = {2026},
volume = {14},
number = {11},
pages = {2562},
doi = {10.3390/microorganisms14112562}
}
EUVIMED